Literature DB >> 24033106

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.

Christopher B Benton1, Farhad Ravandi, Michael Andreeff, Tapan Kadia, Vivian Ruvolo, Peng Qiu, David A Wheeler, Guillermo Garcia-Manero, Jorge Cortes, Hagop M Kantarjian, Marina Konopleva.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24033106      PMCID： PMC4105975          DOI： 10.3109/10428194.2013.840777

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  16 in total

1.  Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

Authors:  Thorsten Braun; Raphael Itzykson; Aline Renneville; Benoit de Renzis; François Dreyfus; Kamel Laribi; Krimo Bouabdallah; Norbert Vey; Andrea Toma; Christian Recher; Bruno Royer; Bertrand Joly; Anne Vekhoff; Ingrid Lafon; Laurence Sanhes; Guillaume Meurice; Cédric Oréar; Claude Preudhomme; Claude Gardin; Lionel Ades; Michaela Fontenay; Pierre Fenaux; Nathalie Droin; Eric Solary
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

2.  Prognostically useful gene-expression profiles in acute myeloid leukemia.

Authors:  Peter J M Valk; Roel G W Verhaak; M Antoinette Beijen; Claudia A J Erpelinck; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Judith M Boer; H Berna Beverloo; Michael J Moorhouse; Peter J van der Spek; Bob Löwenberg; Ruud Delwel
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

3.  Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.

Authors:  Gautam Borthakur; Xuelin Huang; Hagop Kantarjian; Stefan Faderl; Farhad Ravandi; Alessandra Ferrajoli; Ritva Torma; Gail Morris; Donald Berry; Jean-Pierre Issa
Journal:  Leuk Lymphoma       Date:  2010-01

4.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

5.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

6.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Andres O Soriano; Hui Yang; Stefan Faderl; Zeev Estrov; Francis Giles; Farhad Ravandi; Jorge Cortes; William G Wierda; Souzanne Ouzounian; Andres Quezada; Sherry Pierce; Elihu H Estey; Jean-Pierre J Issa; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2007-06-27       Impact factor: 22.113

7.  Antagonism of 5-aza-2'-deoxycytidine antileukemic activity by concomitant treatment with cytarabine.

Authors:  T Colombo; C Rossi; M D'Incalci
Journal:  Cancer Treat Rep       Date:  1986-12

8.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Kati Maharry; Yue-Zhong Wu; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Kelsi B Holland; Susan P Whitman; Heiko Becker; Sebastian Schwind; Klaus H Metzeler; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 50.717

9.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

Review 10.  Cancer-associated IDH mutations: biomarker and therapeutic opportunities.

Authors:  K E Yen; M A Bittinger; S M Su; V R Fantin
Journal:  Oncogene       Date:  2010-10-25       Impact factor: 8.756
View more
  2 in total

Review 1.  IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.

Authors:  Johanna Mondesir; Christophe Willekens; Mehdi Touat; Stéphane de Botton
Journal:  J Blood Med       Date:  2016-09-02

Review 2.  Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.

Authors:  Xiaoyan Liu; Yuping Gong
Journal:  Biomark Res       Date:  2019-10-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.